Abstract:
En
|
Text:
En
|
PDF:
En
ABSTRACT Background: Chronic conditions increase the risk of invasive pneumococcal diseases (IPD). Pneumococcal vaccination remarkably reduced IPD morbimortality in vulnerable populations. In Brazil, pneumococcal vaccines are included in the National Immunization Program (PNI): PCV10 for < 2 years-old, and PPV23 for high risk-patients aged ≥ 2 years and institutionalized ≥ 60 years. PCV13 is available in private clinics and recommended in the PNI for individuals with certain underlying conditions. Methods: A retrospective study was performed using clinical data from all inpatients from five hospitals with IPD from 2016 to 2018 and the corresponding data on serotype and antimicrobial-non-susceptibility of pneumococcus. Vaccine-serotype-coverage was estimated. Patients were classified according to presence of comorbidities: healthy, without comorbidities; at-risk, included immunocompetent persons with specific medical conditions; high-risk, with immunocompromising conditions and others Results: 406 IPD cases were evaluated. Among 324 cases with information on medical conditions, children < 5 years were mostly healthy (55.9%), while presence of comorbidity prevailed in adults ≥ 18 years old (> 82.0%). Presence of ≥1 risk condition was reported in ≥ 34.8% of adults. High-risk conditions were more frequent than at-risk in all age groups. Among high-risk comorbidity (n = 211), cancer (28%), HIV/AIDS (25.7%) and hematological diseases (24.5%) were the most frequent. Among at-risk conditions (n = 89), asthma (16.5%) and diabetes (8.1%) were the most frequent. Among 404 isolates, 42.9% belonged to five serotypes: 19A (14.1%), 3 (8.7%), 6C (7.7%), 4 and 8 (6.2% each); 19A and 6C expressed antimicrobial-non-susceptibility. The vaccine-serotype-coverage was: PCV10, 19.1%, PCV13, 43.8%; PCV15, 47.8%; PCV20, 62.9%; PCV21, 65.8%, and PPV23, 67.3%. Information on hospital outcome was available for 283 patients, of which 28.6% died. Mortality was 54.2% for those with meningitis. Conclusion: Vaccine with expanded valence of serotypes is necessary to offer broad prevention to IPD. The present data contribute to pneumococcal vaccination public health policies for vulnerable patients, mainly those with comorbidity and the elderly. Background . (IPD) populations Brazil (PNI) PCV PCV1 yearsold, yearsold old, years-old PPV PPV2 riskpatients patients 6 Methods 201 antimicrobialnonsusceptibility antimicrobial non susceptibility pneumococcus Vaccineserotypecoverage coverage estimated comorbidities atrisk, atrisk at risk, highrisk, highrisk Results 40 evaluated 32 55.9%, 559 55.9% , 55 9 (55.9%) 1 > ( 82.0%. 820 82.0% 82 0 82.0%) 348 34 34.8 Highrisk High groups n 211, 211 211) 28%, 28 28% (28%) HIVAIDS HIV AIDS 25.7% 257 25 7 (25.7% 24.5% 245 24 (24.5% 89, 89 89) 16.5% 165 16 (16.5% 8.1% 81 (8.1% isolates 429 42 42.9 14.1%, 141 14.1% 14 (14.1%) 8.7%, 87 8.7% (8.7%) C 7.7%, 77 7.7% (7.7%) 6.2% 62 (6.2 each each) antimicrobialnonsusceptibility. susceptibility. vaccineserotypecoverage vaccine 191 19 19.1% 43.8% 438 43 PCV15 47.8% 478 47 PCV20 62.9% 629 PCV21 658 65 65.8% 673 67 67.3% 286 28.6 died 542 54 54.2 meningitis Conclusion elderly (IPD (PNI 20 55.9 (55.9% 82.0 34. 21 (28% 25.7 (25.7 24.5 (24.5 16.5 (16.5 8.1 (8.1 42. 14.1 (14.1% 8.7 (8.7% 7.7 (7.7% 6.2 (6. 19.1 43.8 47.8 PCV2 62.9 65.8 67.3 28. 54. 55. (55.9 82. (28 25. (25. 24. (24. 16. (16. 8. (8. 14. (14.1 (8.7 7. (7.7 6. (6 19. 43. 47. 62. 65. 67. (55. (2 (25 (24 (16 (8 (14. (7. (55 (1 (14 (7 (5